Approved clinical trials
NADH research is ongoing both in the US and in Europe. Currently studies and approved clinical trials are being conducted under the auspices of leading US research hospitals to explore NADH / Co-E1’s full potential. NADH / Co-E1® research data and research study results are available for:

• Chronic Fatigue Syndrome (CFS)
• Alzheimer’s disease
• Depression
• Parkinson’s disease
• Athletic Endurance

The history
In 1993, Dr. Georg Birkmayer, MD, Ph.D., world renowned biochemical researcher and director of the Birkmayer Institute for Parkinson Therapy, Vienna Austria, developed the first and only stable form of NADH. The Birkmayer Institute is dedicated to innovative research approaches to neurological and degenerative diseases.

NADH / Co-E1® availability
NADH is sold under the brand name Co-E1®, and is manufactured and distributed in the United States by the Menuco Corporation. Co-E1® is manufactured under GMP (Good Manufacturing Practice) using a patented process which insures NADH is delivered to the body in a bio-available form. Co-E1® quality is further insured by blister packaging.

If you or your physician, or health care professional would like more information about NADH / Co-E1®
Call us at: 800-928-NADH

The 928 reminds me of a car, the Porsche 928 and the last four digits of the phone number are:

• NADH = Not Accepting Declining Health

. . . new subject begins on the next page